

Resource Summary Report

Generated by [nidm-terms](#) on Aug 10, 2026

Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, DyLight™ 488

RRID:AB_2556714

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# SA5-10134, RRID:AB_2556714

Antibody Information

URL: http://antibodyregistry.org/AB_2556714

Proper Citation: Thermo Fisher Scientific Cat# SA5-10134, RRID:AB_2556714

Target Antigen: Human IgG Fc

Host Organism: goat

Clonality: polyclonal secondary

Comments: Applications: Flow (1:50- 1:200), ICC/IF (1:50-1:500), IHC (1:50-1:500), IP (Assay-dependent), WB (1:5,000-1:20,000)

Antibody Name: Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, DyLight™ 488

Description: This polyclonal secondary targets Human IgG Fc

Target Organism: human

Antibody ID: AB_2556714

Vendor: Thermo Fisher Scientific

Catalog Number: SA5-10134

Record Creation Time: 20250819T233910+0000

Record Last Update: 20250820T060001+0000

Ratings and Alerts

No rating or validation information has been found for Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, DyLight™ 488.

No alerts have been found for Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, DyLight™ 488.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Riquelme MA, et al. (2024) Antibody-activation of connexin hemichannels in bone osteocytes with ATP release suppresses breast cancer and osteosarcoma malignancy. Cell reports, 43(7), 114377.

Patel E, et al. (2024) XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies. Molecular cancer therapeutics, 23(4), 421.